Literature DB >> 18362929

Efficient in vivo delivery of siRNA to the liver by conjugation of alpha-tocopherol.

Kazutaka Nishina1, Toshinori Unno, Yoshitaka Uno, Takayuki Kubodera, Tadashi Kanouchi, Hidehiro Mizusawa, Takanori Yokota.   

Abstract

RNA interference is a powerful tool for target-specific knockdown of gene expression. However, efficient and safe in vivo delivery of short interfering RNA (siRNA) to the target organ, which is essential for therapeutic applications, has not been established. In this study we used alpha-tocopherol (vitamin E), which has its own physiological transport pathway to most of the organs, as a carrier molecule of siRNA in vivo. The alpha-tocopherol was covalently bound to the antisense strand of 27/29-mer siRNA at the 5'-end (Toc-siRNA). The 27/29-mer Toc-siRNA was designed to be cleaved by Dicer, producing a mature form of 21/21-mer siRNA after releasing alpha-tocopherol. The C6 hydroxyl group of alpha-tocopherol, associated with antioxidant activity, was abolished. Using this new vector, intravenous injection of 2 mg/kg of Toc-siRNA, targeting apolipoprotein B (apoB), achieved efficient reduction of endogenous apoB messenger RNA (mRNA) in the liver. The downregulation of apoB mRNA was confirmed by the accumulation of lipid droplets in the liver as a phenotype. Neither induction of interferons (IFNs) nor other overt side effects were revealed by biochemical and pathological analyses. These findings indicate that Toc-siRNA is effective and safe for RNA interference-mediated gene silencing in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362929     DOI: 10.1038/mt.2008.14

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  83 in total

1.  siRNA-aptamer chimeras on nanoparticles: preserving targeting functionality for effective gene silencing.

Authors:  Vaishali Bagalkot; Xiaohu Gao
Journal:  ACS Nano       Date:  2011-09-21       Impact factor: 15.881

Review 2.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

Review 3.  Lipid-Drug Conjugate for Enhancing Drug Delivery.

Authors:  Danielle Irby; Chengan Du; Feng Li
Journal:  Mol Pharm       Date:  2017-01-24       Impact factor: 4.939

4.  Sustained local delivery of siRNA from an injectable scaffold.

Authors:  Christopher E Nelson; Mukesh K Gupta; Elizabeth J Adolph; Joshua M Shannon; Scott A Guelcher; Craig L Duvall
Journal:  Biomaterials       Date:  2011-11-05       Impact factor: 12.479

Review 5.  Advances in Biomaterials for Drug Delivery.

Authors:  Owen S Fenton; Katy N Olafson; Padmini S Pillai; Michael J Mitchell; Robert Langer
Journal:  Adv Mater       Date:  2018-05-07       Impact factor: 30.849

Review 6.  Drug delivery systems and liver targeting for the improved pharmacotherapy of the hepatitis B virus (HBV) infection.

Authors:  María L Cuestas; Verónica L Mathet; José R Oubiña; Alejandro Sosnik
Journal:  Pharm Res       Date:  2010-03-24       Impact factor: 4.200

7.  Intrathecal AAV serotype 9-mediated delivery of shRNA against TRPV1 attenuates thermal hyperalgesia in a mouse model of peripheral nerve injury.

Authors:  Takashi Hirai; Mitsuhiro Enomoto; Hidetoshi Kaburagi; Shinichi Sotome; Kie Yoshida-Tanaka; Madoka Ukegawa; Hiroya Kuwahara; Mariko Yamamoto; Mio Tajiri; Haruka Miyata; Yukihiko Hirai; Makoto Tominaga; Kenichi Shinomiya; Hidehiro Mizusawa; Atsushi Okawa; Takanori Yokota
Journal:  Mol Ther       Date:  2013-10-28       Impact factor: 11.454

Review 8.  Synthetic biology in mammalian cells: next generation research tools and therapeutics.

Authors:  Florian Lienert; Jason J Lohmueller; Abhishek Garg; Pamela A Silver
Journal:  Nat Rev Mol Cell Biol       Date:  2014-01-17       Impact factor: 94.444

Review 9.  Targeted delivery systems for oligonucleotide therapeutics.

Authors:  Bo Yu; Xiaobin Zhao; L James Lee; Robert J Lee
Journal:  AAPS J       Date:  2009-03-19       Impact factor: 4.009

Review 10.  Short non-coding RNA biology and neurodegenerative disorders: novel disease targets and therapeutics.

Authors:  Marc S Weinberg; Matthew J A Wood
Journal:  Hum Mol Genet       Date:  2009-04-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.